Tarsus Pharmaceuticals
Stock Forecast, Prediction & Price Target
Tarsus Pharmaceuticals Financial Estimates
Tarsus Pharmaceuticals Revenue Estimates
Tarsus Pharmaceuticals EBITDA Estimates
Tarsus Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $57.02M N/A | $25.81M -54.73% | $17.44M -32.41% | Avg: $269.58M Low: $227.90M High: $291.10M avg. 1445.13% | Avg: $440.61M Low: $373.30M High: $500.35M avg. 63.44% | Avg: $625.26M Low: $529.75M High: $710.05M avg. 41.90% | Avg: $740.53M Low: $627.41M High: $840.95M avg. 18.43% |
Net Income
% change YoY
| $-13.82M N/A | $-62.09M -349.05% | $-135.89M -118.86% | Avg: $-51.05M Low: $-61.70M High: $3.52M avg. 62.42% | Avg: $115.45M Low: $19.68M High: $123.70M avg. 326.12% | Avg: $144.46M Low: $115.77M High: $169.93M avg. 25.13% | Avg: $193.34M Low: $154.94M High: $227.42M avg. 33.83% |
EBITDA
% change YoY
| $-10.57M N/A | $-59.12M -458.90% | $-131.67M -122.69% | Avg: $-10.00M Low: $-10.80M High: $-8.45M avg. 92.40% | Avg: $-16.34M Low: $-18.56M High: $-13.85M avg. -63.44% | Avg: $-23.19M Low: $-26.34M High: $-19.65M avg. -41.90% | Avg: $-27.47M Low: $-31.20M High: $-23.27M avg. -18.43% |
EPS
% change YoY
| -$0.67 N/A | -$2.52 -276.11% | -$4.62 -83.33% | Avg: -$1.36 Low: -$2.1 High: $0.12 avg. 70.60% | Avg: $2.56 Low: $0.67 High: $4.21 avg. 288.26% | Avg: $4.92 Low: $3.94 High: $5.78 avg. 92.30% | Avg: $6.58 Low: $5.27 High: $7.74 avg. 33.83% |
Operating Expenses
% change YoY
| $67.10M N/A | $87.57M 30.49% | $159.01M 81.57% | Avg: $561.63M Low: $474.80M High: $606.47M avg. 253.20% | Avg: $917.95M Low: $777.73M High: $1.04B avg. 63.44% | Avg: $1.30B Low: $1.10B High: $1.47B avg. 41.90% | Avg: $1.54B Low: $1.30B High: $1.75B avg. 18.43% |
FAQ
What is Tarsus Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 111.87% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -61.70M, average is -51.05M and high is 3.52M.
What is Tarsus Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 392.23% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $227.90M, average is $269.58M and high is $291.10M.
What is Tarsus Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 121.25% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$2.1, average is -$1.36 and high is $0.12.
What is the best performing analyst?
In the last twelve months analysts have been covering Tarsus Pharmaceuticals stock. The most successful analyst is Oren Livnat.